Authors: Federico Bertuzzi,; Roberto Verzaro,; Vincenzo Provenzano,; Camillo Ricordi,

Source: Current Medicinal Chemistry, Volume 14, Number 16, July 2007 , pp. 1739-1744(6)

Publisher: Bentham Science Publishers

Abstract:

A small group of patients affected by type 1 diabetes mellitus is characterized by a severe instability of glycemic values with frequent and unpredictable hypoglycemic and/or ketoacidosis episodes which cannot be explained by errors of patients or diabetologists. The quality of life of these patients is dramatically compromised in particular because of the frequency of acute events, hospital recoveries and precocious appearance of chronic complications. This clinical condition has been defined as “brittle diabetes”. A precise quantification of these patients is difficult because diagnostic criteria are still not well defined and it is often difficult to verify errors of patients in terms of inappropriate conduct with the pathology. Even more than the other kinds of diabetes, therapy is based on education, glycemic control, intensive therapy and strict interaction between physicians and patients. The introduction of insulin analogous, with either ultra-fast and ultra-slow action and the use of subcutaneous insulin pumps have significantly increased the possibility of treating the most of these cases. However, there is a minority of patients resistant to the therapy. In similar cases, pancreas or islet transplantation represents an effective therapeutic option entailing good expected outcomes. The main limiting factor of beta cell function replacement by transplantation is so far represented by the potentially severe side effects of the immunosuppression therapy necessary to avoid graft rejection and recurrence of autoimmunity.

Keywords: Brittle diabetes mellitus; insulin analogues; continuous subcutaneous insulin infusion; immunosuppression therapy; islet transplantation; pancreas transplantation

Document Type: Research article

DOI: http://dx.doi.org/10.2174/092986707781058922

Affiliations: 1: Head, Diabetes Unit, ISMETT, via Tricomi 1, 90127 Palermo, Italy.

Publication date: 2007-07-01

More about this publication?

• Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Federico Bertuzzi, ;  Roberto Verzaro, ;  Vincenzo Provenzano, ;  Camillo Ricordi,

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers